What the ASPS 2024 Procedural Statistics Mean for Your Patient Pipeline

Update: ASPS released its 2025 report on September 1, 2026. Read our breakdown of what the 2025 statistics mean for your practice.

Each year the American Society of Plastic Surgeons (ASPS) publishes its procedural statistics, the most widely cited snapshot of aesthetic demand in the United States. The 2024 report, released in June 2025, is worth reading closely, not for the headline numbers alone but for what they imply about where patients will come from next.¹

The headline: a stable market

ASPS reported nearly 1.6 million cosmetic surgical procedures in 2024, a 1% increase over the prior year, alongside more than 28.5 million minimally invasive treatments, up 1.5%.¹

That is steady demand, not explosive growth. For an individual practice, it means new surgical volume will come mostly from winning a larger share of an existing market, not from the market expanding around you. Positioning and patient experience matter more in a flat market than in a booming one.

Five procedures lead surgical demand

Source: ASPS 2024 Procedural Statistics.¹

If your website and advertising do not have dedicated, well-structured content for each procedure you offer from this list, you are likely missing the patients who search for them by name.

The GLP-1 patient is already here

The report also highlighted patients using GLP-1 weight-loss medications. According to ASPS, 20% of GLP-1 patients under the care of ASPS member surgeons have already had plastic surgery, 39% are considering a surgical procedure, and 41% are considering a nonsurgical one.¹

These patients often arrive with specific concerns about skin laxity and body contouring after significant weight loss. Educational content that addresses their situation directly, without overpromising, is one of the clearest opportunities in the report.

Nonsurgical patients are your warmest pipeline

Neuromodulator injections alone accounted for more than 9.8 million treatments in 2024, and hyaluronic acid fillers for more than 5.3 million.¹ Many surgical patients start as injectable patients. A practice that stays in thoughtful contact with its nonsurgical patients, and reactivates past inquiries, is sitting on a pipeline that costs nothing in ad spend to reach.

What to do with this in 2026

1. Build procedure-level content for each of your core procedures, answering cost, recovery, and candidacy questions in plain language.
2. Create a post-weight-loss pathway: an education page and a consultation track for patients who have lost weight with GLP-1 medications.
3. Reactivate before you advertise. Past inquiries and nonsurgical patients are the lowest-cost source of new consultations.
4. Compete on authority, not price. In a stable market, the practice patients trust most wins the share.

Note: ASPS data reflects the U.S. market. Canadian practices should treat it as directional rather than a direct measure of local demand.